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Abstract
Histone deacetylase inhibitors (HDACi) are promising anti-cancer agents, however, their mechanisms of action remain
unclear. In acute myeloid leukemia (AML) cells, HDACi have been reported to arrest growth and induce apoptosis. In this
study, we elucidate details of the DNA damage induced by the HDACi vorinostat in AML cells. At clinically relevant
concentrations, vorinostat induces double-strand breaks and oxidative DNA damage in AML cell lines. Additionally, AML
patient blasts treated with vorinostat display increased DNA damage, followed by an increase in caspase-3/7 activity and a
reduction in cell viability. Vorinostat-induced DNA damage is followed by a G2-M arrest and eventually apoptosis. We found
that pre-treatment with the antioxidant N-acetyl cysteine (NAC) reduces vorinostat-induced DNA double strand breaks, G2-
M arrest and apoptosis. These data implicate DNA damage as an important mechanism in vorinostat-induced growth arrest
and apoptosis in both AML cell lines and patient-derived blasts. This supports the continued study and development of
vorinostat in AMLs that may be sensitive to DNA-damaging agents and as a combination therapy with ionizing radiation
and/or other DNA damaging agents.
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Introduction
Histone Deacetylases (HDACs) catalyze the removal of acetyl
groups from e-lysine residues of histones resulting in chromatin
condensation and gene silencing. HDAC overexpression and
aberrant recruitment to the promoters of genes implicated in
differentiation and tumor suppression has been reported in a
number of malignancies [1,2]. HDACs can be divided into four
classes: class I (HDAC1, 2, 3, and 8), class IIa (HDAC4, 5, 7, and
9), class IIb (HDAC6 and 10), class III (SIRT1, 2, 3, 4, 5, 6, and 7)
and class IV (HDAC11) [3]. Class I, II and IV are zinc-dependent
deacetylases, while Class III is NAD
+-dependent [3,4]. HDACs
can also remove acetyl residues from non-histone proteins, thereby
altering their function, providing another mechanism by which
HDACs may participate in the malignant phenotype. Targeting
HDAC activity using pharmacological small molecule HDAC
inhibitors (HDACi) has become an exciting therapeutic strategy.
Early studies correlated the anti-tumor effects of HDAC inhibition
with restoration of expression of genes involved in differentiation
and tumor suppression [5,6]. However, subsequent microarray
studies found that HDACi directly or indirectly activate only 7–
10% of all genes, with roughly the same number repressed [7].
This suggested that the anti-tumor activities of HDACi were not
limited to their effects on transcription. Indeed, a recent study
found 1750 proteins to be acetylated in response to HDACi [8],
further suggesting that HDACi can influence diverse cellular
pathways.
While HDACi were initially associated with differentiation
therapy [9,10], recent work with HDACi has expanded into
understanding mechanisms of HDACi cytotoxicity. All HDACi
have been reported to arrest growth and to activate the extrinsic
and/or the intrinsic apoptotic pathways [3]. Additionally, HDACi
have been shown to inhibit tumor growth in animal models
[11,12]. One mechanism by which HDACi are thought to cause
cancer cell apoptosis is through the induction of DNA damage and
genomic instability [13]. This has been shown to occur through
the generation of reactive oxygen species (ROS), deregulation of
repair proteins by acetylation and repression of DNA damage
repair protein expression [13,14,15]. It is worth mentioning that
normal cells have been reported to be significantly less sensitive
than tumor cells to all these effects [16].
Vorinostat (suberoylanilide hydroxamic acid, Zolinza
TM)i sa
broad spectrum HDACi that inhibits zinc-dependent HDACs
(Class I, II and IV). Vorinostat received FDA approval for use in
Cutaneous T-cell lymphoma (CTCL) and is in clinical trials, both
as a single agent and in combination with other agents in a
number of other malignancies [17]. It has also been shown to
induce ROS and DNA damage in a number of tumor types
[13,18]. Nonetheless, the characterization of vorinostat in acute
myeloid leukemia (AML) cells remains incomplete.
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species, growth arrest and apoptosis in leukemia cells and leukemia
mouse models [19,20,21,22]. However, the ability of vorinostat to
induce DNA damage in leukemia cells is yet to be reported. In this
study, we investigated the mechanisms by which vorinostat-
induced DNA damage affects cell growth and apoptosis. We show
for the first time that at low, clinically achievable doses, vorinostat
induces a variety of DNA damage in leukemia cell lines and AML
patient-derived blasts cultured ex vivo. These data demonstrate
DNA damage to be a contributor to vorinostat-mediated growth
arrest and apoptosis mechanisms.
Materials and Methods
Ethics Statement
Patient samples obtained from the Quebec Leukemia Cell Bank
were collected in accordance with the ethical requirements and
regulations of the Quebec Leukemia Cell Bank Ethics Committee.
Ethical approval for this study was obtained from the Jewish
General Hospital and the McGill Institutional Review Board. All
patient samples obtained, collected and used were done so in
accordance to the ethical requirements and regulations of the
Jewish General Hospital and the McGill Institutional Review
Board. Informed written consent was obtained from all partici-
pants involved.
Cell lines, patient cells and reagents
Vorinostat was obtained courtesy of Merck (Whitehouse
Station, NJ, USA) and dissolved in DMSO. Z-VAD-FMK was
purchased from Promega. N-acetyl cysteine (NAC) was purchased
from Sigma and dissolved in DMEM. NB4 and U937 cells were
obtained from ATCC and cultured in RPMI supplemented with
10% fetal bovine serum (FBS) at 37uC with 5% CO2. Peripheral
blood mononuclear cells (PBMCs) from healthy volunteers and
blasts from patient FG04290 (AML type M3) and 281010 (AML
inv(3)) were isolated from blood samples obtained with patient
informed consent. Briefly, blood was centrifuged and the serum
discarded. Cells were then resuspended in HBSS, layered over
Ficoll and centrifuged. Blasts that remained suspended in the
Ficoll were collected for cell culture and treatment. Cryopreserved
blasts from patients 03-H070 and 07-H020 (type M3) were
obtained from the Quebec Leukemia Cell Bank (Maisonneuve-
Rosemont Hospital).
COMET assay
COMET assays was performed under alkaline or neutral
conditions as previously described [23]. Briefly, cells were
imbedded in low melting point agarose and layered onto glass
slides (Trevigen). Slides were incubated in lysis buffer overnight at
4uC. Slides were then washed and incubated in alkaline buffer
(pH.13) for 30 minutes. The COMET slides were then subjected
to electrophoresis at 20 V and 240 mA for 30 minutes. After-
wards, the slides were washed in distilled water and fixed using
70% ethanol. Finally, cells were stained with ethidium bromide
(1 mg6mL
21). Images were randomly collected for analysis of at
least 100 nuclei in duplicate experiments using a fluorescent
microscope (Leica). Comets were scored using CometScore
(TriTek) for tail moment (TM) and tail length (TL). TM and TL
are presented in arbitrary units (a.u).
Western analysis
Whole cell extracts were prepared from pelleted cells lysed in
RIPA buffer (150 mM sodium chloride, 1.0% Triton X-100, 0.5%
sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0). Western
blot was performed on extracts to detect protein levels of
cH2AXser139, NBS1 (Cell Signaling), Ku70, cyclin-E and
RAD51 (Santa Cruz Biotechnology). b-Actin was purchased from
Sigma and confirmed equal protein loading.
BrdU-PI staining
BrdU was added to cells in culture for 15 minutes, collected,
washed twice in warm PBS, and fixed in ice cold 70% ethanol.
Fixed cells were then washed twice in PBS and once in PBS with
0.1% BSA. Finally, cells were incubated with BrdU-FITC
conjugated antibody, washed and counterstained with propidium
iodide. Samples were analyzed using a FACSCalibur flow
cytometry (BD Bioscience) and FCS Express v3.0 (De Novo
Software). Ten thousand events were collected per sample.
Quantification of cH2AXser139 and P-Ser10-H3 by flow
cytometry
Cells were treated and fixed in 1% paraformaldehyde.
Afterwards, cells were permeabilized by 1% Triton dissolved in
PBS. Permeabilized cells were incubated with a FITC-conjugated
antibody directed against cH2AXser139 or P-Ser10-H3 at room
temperature. Cells were concomitantly stained with propidium
iodide to assess DNA content. Fluorescence was measured by flow
cytometer and analyzed using FCS Express v3.0. Ten thousand
events were recorded per sample.
Propidium iodide staining
Cells were seeded at 2610
5cells6mL
21 and treated as described.
Subsequently, cellswerecollectedandwashedinsupplemented PBS
(5% FBS/0.01 M NaN3)a t4 uC, pelleted, and resuspended in a
hypotonic fluorochrome solution (50 mg?ml
21propidium iodide,
0.1% sodium citrate, 0.1% Triton X-100). Fluorescence was
detected by flow cytometry and analysis was performed using
FCS Express v3.0. Ten thousand events were recorded per sample
and allowed for investigation of cell cycle and apoptosis. Cells
undergoing DNA fragmentation and apoptosis were defined as
events with fluorescence weaker than the Go-G1 cell cycle peak
(Sub-Go).
ROS Detection
Cells were treated with vorinostat for 6 h and 18 h. Cells were
then incubated with 25 mg/ml 29-79-dichlorofluorescin diacetate
(DCF-DA) for 30 minutes at 37uC for the detection of intracellular
peroxides (mainly H2O2). Cells were collected and washed in PBS.
Fluorescence was measured by flow cytometry and analyzed using
FCS Express v3.0.
Cell viability and caspase-3/7 assay
Cell viability was assayed using CellTiter-GloH Luminescent
Cell Viability Assay (Promega). This assay aims to quantify the
amount of ATP present as this correlates with the number of
metabolically viable cells in culture. Briefly, cells treated with
vorinostat were incubated in a cell lysis solution containing a
luciferin derivative, Ultra-Glo
TM Recombinant Luciferase and
Mg
2+ for 10 minutes at room temperature. The solution lyses the
cells and converts the luciferin derivative into a luminescent signal
proportional to the amount of ATP present. Caspase-3/7 activity
was assayed using Caspase-Glo 3/7H Assay (Promega). Briefly,
cells treated with vorinostat were incubated in a cell lysis solution
containing a luciferase substrate derivative, Ultra-Glo
TM Recom-
binant Luciferase and Mg
2+ for 1 hour at room temperature. The
luciferase substrate derivative is specifically cleaved by active
caspase-3/7 resulting in the conversion of the substrate into a
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FLUOstar OPTIMA microplate reader (BMGLabtech). The
luminescent signal was then normalized to cell number and is
reported as RLU/cell.
Glutathione Quantification
Glutathione (GSH) was quantified using GSH-Glo Glutathione
Assay (Promega). Briefly, cells were counted and washed with PBS.
For each condition, 10 000 cells were plated. Cells were then
incubated in a solution containing a luciferin derivative and
Glutathione S-Transferase for 30 min at room temperature. In the
presence of GSH, the luciferin derivative is converted to luciferin.
The cells were then incubated with luciferase enzyme, which
initiates a luminescence signal directly proportional to the luciferin
previously generated. Luminescence was measured using a
FLUOstar OPTIMA microplate reader. Serial dilution of a
GSH standard solution was included in order to generate a
standard curve, facilitating the conversion of RLU to GSH
concentration. Cells treated with buthionine sulphoximine (BSO)
were also included as a control.
Statistics
Significance was determined by ANOVA followed by Newman-
Keuls post-tests using Prism version 4.0 (GraphPad).
Results
Vorinostat induces a variety of DNA damage in AML cells
Previously, vorinostat has been shown to induce DNA double
strand breaks (DSBs) [24]. To investigate the possibility of other
types of DNA damage, we performed a comprehensive analysis of
vorinostat-induced DNA damage. Two AML cell lines, NB4 and
U937, were treated with equally cytotoxic and clinically achievable
concentrations of vorinostat before being subjected to single-cell
gel electrophoresis (COMET assay). The COMET assay was
performed under alkaline conditions, as this permits the detection
of a broad spectrum of DNA lesions including DSBs, DNA single-
strand breaks and alkalile-labile sites. Treatment with vorinostat
caused a significant increase in COMET tail moment and tail
length (Figure 1A). To specifically assess vorinostat-induced DSBs,
the COMET assay was also performed under neutral conditions,
which makes the assay more specific to DSBs but still allows for the
detection of cross-links. Indeed, a significant increase in tail
moment and tail length was observed and increased in a time-
dependent manner (Figure 1B). To verify induction of DSBs,
phosphorylation of H2AX was measured by western blot. The
phosphorylated form of H2AX (cH2AX) localizes to DSBs within
minutes of their formation and is therefore a sensitive marker for
this lesion [25]. Vorinostat induced cH2AX after 12 h of
treatment in both NB4 and U937 cells (Figure 1C). It should be
noted that an increase in cH2AX could be observed after 6 h of
vorinostat when blots were over-exposed (data not shown). Also, a
number of studies have shown that vorinostat induces ROS.
Therefore, we assayed for oxidative DNA damage by staining cells
with a fluorescent antibody that recognizes 8-oxoguanine (8-
oxo-G) and quantified its induction by flow cytometry. This DNA
adduct is a sensitive marker of oxidative stress. We detected an
early and time-dependent increase of 8-oxo-G in both NB4 and
U937 cells (Figure 1D). Collectively, these data demonstrate that
vorinostat is able to induce a variety of DNA damage including
DSBs and oxidative DNA lesions.
Vorinostat increases DNA replication and induces a G2-M
arrest followed by apoptosis
DNA damage is often accompanied by arrest in cell cycle, and
HDACi have been shown to cause a G2-M and/or G1 arrest
depending on the malignancy/model and HDACi concentration
used. To determine if vorinostat-induced DNA damage resulted in
a cell cycle arrest, we performed a double-stain with BrdU
(incorporates into replicating cells) and PI (provides a measure of
DNA content). The BrdU-PI stain allows for gating and accurate
calculation of the percentage of cells in each phase of the cell cycle
and discriminates late S-phase from G2 cells and early S-phase
cells from G1, as opposed to only staining with PI. We observed a
substantial increase in BrdU negative cells with 4N DNA content
(G2-M phase) after 6 h–12 h of vorinostat with a decrease in BrdU
negative cells with 2N DNA content (G1 phase) (Figure 2A). This
demonstrates that vorinostat induces a G2-M phase arrest
consistent with the appearance of DNA damage.
We detected a slight increase in replicating cells (BrdU positive
cells), which is supported by an increase in cyclin-E as detected by
western blot (Figure 2B). To further characterize the G2-M arrest,
a double-stain with histone H3 phosphorylated at serine 10 (P-
Ser10-H3), a marker of mitosis, and PI was performed and
quantified by flow cytometry. Vorinostat was able to induce P-
Ser10-H3 and, as previously shown, caused an accumulation of
cells with a G2-M DNA content (Figure 2C). However, there was
no change in the ratio of P-Ser10-H3 positive cells to cells
arresting in G2-M. This suggests that the cell cycle arrest is not
specific to the G2-phase or mitosis. Taxol was used as a positive
control, as it stabilizes microtubules, causing cells to arrest in
mitosis resulting in a significant increase in the percentage of P-
Ser10-H3 positive cells within the G2-M population [26]. Next, to
determine if the cells arresting in G2-M have damaged DNA, a
double-stain with cH2AX and PI was performed and quantified
by flow cytometry. The cH2AX-PI stain demonstrated that
vorinostat induces a significant increase of cH2AX positive cells
arresting in G2-M versus vehicle treated control (Figure 2D). This
suggests that cells with DSBs eventually arrest and accumulate in
the G2-M phase. Importantly, the cH2AX positive cells were not
predominantly found in the Sub-Go population. This indicates
that cH2AX is not induced solely as a consequence of apoptosis.
These data suggest that vorinostat causes cells to exit the G1 phase
of the cell cycle and that cycling cells from G1 eventually arrest in
the G2-M phase, likely due to an accumulation of DNA damage.
To assay for cell death, NB4 and U937 cells were treated with
vorinostat and subsequently stained with PI in order to quantify
fragmented DNA by flow cytometry. Vorinostat induced cell death
in a dose- and time-dependent manner in both NB4 and U937
Figure 1. Vorinostat induces different types of DNA damage in NB4 and U937 cells. NB4 and U937 cells were treated with 1.5 mM and
2.0 mM vorinostat, respectively, for the indicated time points. A Alkaline COMET assay to measure DNA double strand breaks, single-strand breaks and
alkalile-labile sites. At least 100 nuclei were randomly selected and quantified for DNA damage, represented as an increase in Tail Moment (a.u) and
Tail Length (a.u). Representative images of COMET tails obtained are presented in the lower panel. B Neutral COMET assay to measure DNA double
strand breaks. DNA double strand breaks are represented as Tail Moment (a.u) and Tail Length (a.u). C Time-dependent induction of cH2AX in
response to vorinostat as measured by western blot. b-Actin was used as a loading control. D Induction of the oxidative DNA lesion 8-oxoguanine in
response to vorinostat was quantified by flow cytometry using a FITC-conjugated antibody. Asterisks show significant difference and a non-
significant difference is indicated as ‘‘n.s’’. (** ,0.01 *** ,0.001).
doi:10.1371/journal.pone.0020987.g001
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of cell cycle arrest, which was observed after 6 h–12 h of
vorinostat treatment, no significant cell death until at least 18 h
post-treatment (data not shown). We next assessed caspase-
dependency of cell death using PI staining and a caspase-3/7
activity assay. Vorinostat induced caspase-3/7 activity in NB4
and U937 cells after 24 h of treatment, consistent with the
appearance of cell death (Figure 3B). Inhibition of caspase activity
by the pan-caspase inhibitor Z-VAD-FMK, suppressed vorino-
stat-induced cell death (Figure 3C). Thus, DNA damage and G2-
M arrest precedes vorinostat-induced apoptosis and this apoptosis
is largely caspase-driven.
Figure 3. Vorinostat induces apoptosis in AML cells following the induction of DNA damage and cell cycle arrest. NB4 and U937 cells
were treated with vorinostat and assayed for apoptosis at the indicated time points. A Cells were stained with PI and analyzed by flow cytometry.
Apoptosis was quantified as the percentage of cells with DNA content below that of the Go-G1 peak (Sub-Go). B Cells were counted and then
assayed for caspase-3/7 activity using a luciferase-based assay, where reactive light units (RLU) are normalized to number of cells. C Cells were pre-
treated with 50 mM Z-VAD-FMK, a pan-caspase inhibitor for 1 h and then treated with vorinostat for 48 h. Apoptosis was then quantified as
percentage of cells with Sub-Go DNA content.
doi:10.1371/journal.pone.0020987.g003
Figure 2. Vorinostat causes cells to arrest in the G2-M phase of cell cycle and arrested cells have accrued DNA double strand
breaks. A Cells were double stained with BrdU and PI, and analyzed by flow cytometry. Graphs show quantification of cells in each phase of the cell
cycle: cells arrested in G1 phase (BrdU negative; 2N DNA content), in S phase (BrdU positive) and in G2-M phase (BrdU negative; 4N DNA content).
B Western blot analysis of cyclin-E expression in NB4 cells treated with vehicle or 1.5 mM vorinostat. b-Actin was used as a loading control. C Cells
were double stained with an antibody against P-Ser10-H3 and PI, and analyzed by flow cytometry. For DNA content, 1=Sub-Go, 2=G1, 3=S and
4=G2-M. Dot plots are representative of data collected and show an increase in mitotic cells positive for P-Ser10-H3, and an accumulation of cells in
G2-M. Graphs show that the ratio of P-Ser10-H3 positive cells to cells with 4N DNA content (G2-M) does not change in response to vorinostat. D Cells
were double stained for cH2AX and PI. Dot plots are representative of data collected and show an increase in cH2AX positive cells that is most
significantly increased in G2-M. The graphs demonstrate an increase in the percentage of cH2AX positive cells amongst the cells arrested in the G2-M
cell cycle phase. Asterisks indicate a significant difference and a non-significant difference is indicated as ‘‘n.s’’ (** ,0.01 *** ,0.001).
doi:10.1371/journal.pone.0020987.g002
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antioxidants reduce vorinostat-induced DNA damage
and apoptosis
Previous studies have reported that HDACi treatment results in
ROS production and ROS has subsequently been postulated to be
a key mechanism in HDACi-induced apoptosis [3]. We analyzed
the production of peroxides (mainly hydrogen peroxide) by DCF-
DA staining in NB4 and U937 cells after treatment with vorinostat
for 6 h or 18 h. Consistent with the induction of the oxidative
stress DNA adduct 8-oxo-G (Figure 1D), we observe an increase in
peroxides beginning at 6 h in both cell lines (Figure 4A). To
validate this finding we assayed for HO-1 protein expression, a
marker of cellular oxidative stress. Treatment of NB4 and U937
cells with vorinostat resulted in the up-regulation of HO-1 protein
beginning at 6 h (Figure 4B). Augmented ROS levels can be due
to a decrease in intracellular GSH, however, at a time point
preceding the appearance of ROS, vorinostat was not found to
alter GSH levels (Figure S1A).
If left unrepaired, DNA adducts including 8-oxo-G can give rise
to DSBs, the most cytotoxic DNA lesion. To determine if ROS-
induced DNA damage may contribute to vorinostat-induced
apoptosis, NB4 cells were pre-treated with the antioxidant NAC
for 1 h prior to treatment with vorinostat. Pre-treatment with this
antioxidant resulted in a significant reduction in vorinostat-
induced DSBs, as measured by cH2AX protein expression
(Figure 4C). Pre-treatment with NAC was also associated with a
reduction of cells arresting at the G2-M cell cycle phase (Figure
S1B) and a partial protection in vorinostat-induced apoptosis
(Figure 4D). In addition to NAC, the antioxidants L-GSH and
MnTMPyP, a superoxide dismutase mimetic, also protected
against vorinostat induced apoptosis in NB4 and U937 cells
(Figure S1C).
Figure 4. Vorinostat mediated DNA damage and apoptosis is in part due to reactive oxygen species. A NB4 and U937 cells were treated
with vorinostat for 6 h and 18 h and stained with DCF-DA to quantify intracellular peroxides. B NB4 and U937 cells were treated with vorinostat for
6 h, 12 h and 18 h and induction of HO-1 was assessed by western blot. b-Actin was used as a loading control. C U937 cells were pre-treated with
2 mM N-acetyl cysteine (NAC), an antioxidant, followed by 2.0 mM vorinostat for 18 h. Induction of cH2AX was assessed by western blot. b-Actin was
used as a loading control. D Cells were stained with PI after 24 h of exposure to vorinostat and/or N-acetyl cysteine, and apoptosis was quantified as
percentage of cells with Sub-Go DNA content. Asterisks show significant difference (** ,0.01 *** ,0.001).
doi:10.1371/journal.pone.0020987.g004
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and reduces their viability
To extend our findings, leukemic blasts from AML patients were
cultured and treated with vorinostat ex vivo, and DNA damage was
assessed using the COMET assay. Vorinostat caused a significant
increase in tail moment, beginning 12 h post vorinostat treatment
(Figure 5A). The increase in DNA damage correlated with a
decrease in cell viability (Figure 5B) and an increase in caspase-3/7
activity (Figure 5C), measured at a later time point (72 h). Blasts
from an additional AML patient were assayed for caspase-3/7
activity in response to vorinostat and/or NAC. In these blasts,
vorinostatcausedasignificantincreasecaspase-3/7activityand pre-
treatment with NAC abolished this increase (Figure S2). These data
confirm that, as in our AML cell line models, treatment of AML
patient blasts with vorinostat results in an early induction of DNA
damage followed at later time points by a decrease in cell viability
and apoptosis. In addition, they also suggest vorinostat-induced
ROS as an important contributor to vorinostat-induced apoptosis
and possibly DNA damage. Importantly, vorinostat did not induce
DNA damage in PBMCs collected from healthy volunteers, as
measured by alkaline comet assay (Figure S3A). Normal PBMCs
also demonstrated a reduced sensitivity to vorinostat-induced loss of
cell viability and apoptosis (Figure S3B, and C).
Discussion
HDACs are overexpressed in many tumor types and have been
shown to play an important role in mediating aberrant epigenetic
reprogramming, silencing tumor suppressor genes and favoring
Figure 5. Vorinostat induces DNA damage and apoptosis at clinically achievable concentrations in AML-patient derived blasts
cultured ex vivo.AAlkaline COMET assay measures DNA double strand breaks, single strand breaks and alkalile-labile sites. DNA damage is
represented as an increase in Tail Moment (a.u.) after 12 h exposure to vorinostat. B Cells were assayed for viability 72 h post-vorinostat treatment
using a luciferase based assay. CC aspase-3/7 activity (normalized to cell number) was assessed as a marker of apoptosis.
doi:10.1371/journal.pone.0020987.g005
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molecule HDACi. Currently, two HDACi (vorinostat and
romidepsin) have garnered FDA approval, both for the treatment
of CTCL [28,29]. One manner by which HDACi have been
proposed to induce cell death is through the induction of DNA
damage and/or genomic instability. In this work, we have
performed a careful analysis of a clinically relevant HDAC
inhibitor, vorinostat, on DNA damage, cell growth and apoptosis.
For the first time, we show that vorinostat induces DNA damage
followed by a G2-M arrest (Figure 6). This DNA damage
correlates with increased apoptosis in leukemic cell lines
(Figure 6) and, importantly, increased apoptosis in primary
leukemic blasts.
Vorinostat is FDA approved for the treatment of CTCL, where
it is administered at a dose of 400 mg once daily [29]. In CTCL
patients this regimen resulted in a maximum concentration
1.260.53 mM. The same regimen in patients with advanced solid
malignancies resulted in a maximum concentration of
1.8160.70 mM [30]. Recently, maximum concentrations of
4.8062.8 mM vorinostat have been achieved in patients using a
pulse dose approach [31]. The doses used in this study to induce
DNA damage and apoptosis in AML cells are within the clinically
achievable range. At lower doses vorinostat does not induce
apoptosis but rather growth arrest and differentiation [20]. We
speculate that the DNA damage inflicted at the higher vorinostat
doses is a sufficiently traumatic event to trigger apoptosis, and as
such is an important factor determining whether the cells will
growth arrest or die. Consistent with a previous report [16], we
find DNA double strand breaks (DSBs) to be induced by vorinostat
as early as 6 h (by neutral COMET assay) coinciding with the
induction of cH2AX (Figure 1). The induction and persistence of
DSBs we observe may be due to a number of mechanisms. For
example, HDACi have previously been shown to induce DSBs or
inhibit their repair by down-regulating expression of DNA repair
proteins including NBS1, BRAC1/2, Ku70, Ku80 and RAD51
[15,32,33]. However, we were unable to detect any reduction in
Ku70, RAD51 or NBS1 protein levels in vorinostat treated NB4
or U937 cells (Figure S4). This leads us to hypothesize that the
DSBs may be due altered repair protein function [14] or
modulation of the DNA damage ‘‘histone-code’’ [34,35,36]. It is
worth noting that malignant cells have been shown to be more
sensitive to HDACi induced DNA damage and apoptosis than
non-malignant cells [37,38], an observation that we confirmed in
vorinostat-treated leukemic blasts, compared to normal PBMCs
(Figure S3).
Of interest is a recent study where vorinostat treatment in
MCF-7 breast cancer cells induced DSBs that were found to co-
localize with replication factories and correlated with a slight
decrease in DNA replication and a significant reduction in
replication fork velocity [24]. Using similar methods (BrdU
incorporation) we show the opposite observation that vorinostat
increases DNA replication in NB4 and U937 cells. It is tempting to
speculate that in our cell lines, the increase in DNA replication
results in a greater amount of DNA damage compared to in MCF-
7 cells, where vorinostat-induced damage results in the arrest of
replication forks. In addition, MCF-7 cells arrest both in G1 and
G2-M in response to vorinostat, possibly limiting the effect of
vorinostat-induced DNA damage and cell death. Indeed, in these
cells, higher doses of vorinostat (4–10 mM) are generally required
to slow DNA replication, induce cell cycle arrest or apoptosis and
even then the apoptosis observed is relatively modest [24,39].
Interestingly, inhibiting the G1-phase arrest has been demonstrat-
ed to sensitize MCF-7 cell to HDAC inhibitor-induced apoptosis
[40]. In contrast, NB4 and U937 cells are unable to mount a G1-
phase arrest in response to vorinostat, possibly leading to a greater
accumulation of DNA damage and more cell death. This is
supported by the significant increase in cH2AX positive cells
arresting in G2-M in response to vorinostat (Figure 2). It is also of
general interest to mention that while capable of a G1-arrest [41],
U937 cells do not arrest at the G1-phase in response to vorinostat,
Figure 6. Treatment of acute myeloid leukemia cells with vorinostat results in an early induction of reactive oxygen species. The
production of reactive oxygen species coincides with the appearance of DNA damage and partially contributes to the DNA damage accumulated.
Reactive oxygen species production and accrual of DNA damage is followed by a G2-M cell cycle arrest and finally apoptosis at later time points.
doi:10.1371/journal.pone.0020987.g006
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inducer of the G1-phase arrest. Consistent with this observation,
p21 expression does not coincide with a degradation of cyclin-E
(Figure 2B).
A number of studies have reported that vorinostat induces ROS
in leukemic cells [18,42] and other malignant cell types [43,44].
To expand on these findings, we found that vorinostat induced 8-
oxo-G, a marker of oxidative DNA damage (Figure 1D). It should
be noted that the increase in vorinostat-induced 8-oxo-G was
statistically significant in U937 but not NB4 cells. 8-oxo-G
represents a single oxidative lesion and vorinostat may induce
other oxidative lesions like 2,6-diamino-4-hydroxy-5-formamido-
pyrimidine, 3-methyladenine and/or 7-methyladenine to a greater
extent in NB4 cells. The ability of vorinostat to induce such
oxidative lesions will be assessed in future studies. The persistence
of such damaged bases can lead to increasingly cytotoxic lesions
such as DSBs [45]. Indeed, pre-treatment with NAC greatly
diminished vorinostat-induced cH2AX, resulting in both a
reduced G2-M phase arrest and apoptosis (Figure 4). However,
the reduction in apoptosis by NAC is modest and highlights the
possibly pleiotrophic mechanisms of vorinostat-induced DNA
damage and apoptosis. Indeed, HDACi have been demonstrated
to activate both death receptor (extrinsic) and mitochondrial
(intrinsic) apoptotic pathways. HDACi have been shown to up-
regulate death ligands TRAIL, TRAIL-R2, Fas, Fas-L and TNFa
of the extrinsic pathway [3]. HDACi have also been shown to
induce pro-apoptotic genes (i.e. Bmf, Bim, Bax, Puma, Noxa) and
down-regulate pro-survival genes (i.e. survivin, XIAP) favoring
initiation of the intrinsic apoptotic program [3].
Finally, we investigated DNA damage in primary leukemic
blasts. Consistent with our findings in cell lines, vorinostat-induced
DNA damage could be measured at an early time point
(Figure 5A). The induction of DNA damage by vorinostat was
also consistent with a reduction in cell viability and an increase in
caspase-3/7 activity (Figure 5B, 5C). It is interesting to note that
while patient-derived leukemia blasts cultured ex vivo do not cycle,
DNA damage is still induced in response to vorinostat. It is
possible that in the context of this model, vorinostat-induced DNA
damage is replication-independent and transcription-dependent,
as previously demonstrated by Conti et al. [24].
In the clinic, the results of vorinostat monotherapy have been
mixed [46,47]. Our data demonstrate that DNA damage is a
relevant mechanism of vorinostat-induced cytotoxicity in AML
cells. We propose the assessment of DNA damage in patients
treated with vorinostat to ascertain whether the induction of DNA
damage correlates with response. Our findings suggest that AML
patients unable to mount a G1-phase arrest to vorinostat may
respond favorably. Indeed, future directions will be aimed at
understanding the mechanisms by which vorinostat bypass the
G1-phase arrest in our cell line models. The existence of numerous
mechanisms by which vorinostat promotes genomic instability
suggests the combination of vorinostat with other DNA damaging
agents, or possibly G1-arrest inhibitors. Indeed, vorinostat along
with other HDACi have been demonstrated to enhance sensitivity
to ionizing radiation and DNA damaging drugs such as mitomycin
C, cisplatin, bleomycin, doxorubicin, etoposide, 5-fluorouracil,
Ara-C and topotecan [48,49]. Alternatively, the many mecha-
nisms of vorinostat may complicate more precisely targeting a
desired cellular function, thereby lessening its therapeutic efficacy.
For example, the vorinostat target HDAC3 has been meticulously
demonstrated in knockout and knockdown experiments to be vital
to DSB repair [24,50]. Thus, the development of more specific
HDACi that target a single HDAC class or isoform may be a
promising approach to improve efficacy of this novel class of anti-
cancer agents.
Supporting Information
Figure S1 Vorinostat does not alter intracellular GSH,
and antioxidants reduce vorinostat-induced G2-M arrest
and apoptosis. A GSH levels were quantified after a 4 h
treatment with vorinostat in NB4 and U937 cells. BSO inhibits
GSH synthesis and was used as a control. B NB4 and U937 cells
were pre-treated for 1 h with NAC followed by vorinostat
treatment for 18 h. Afterwards, the cells were stained with
propidium iodide to measure DNA content. C NB4 and U937
cells were pre-treated for 1 h with the antioxidant L-GSH or the
SOD mimetric MnTMPyP for 1 h followed by vorinostat
treatment for 24 h. Cells were then stained with propidium iodide
to quantify DNA fragmentation. Asterisks indicate a significant
difference (*** ,0.001).
(TIF)
Figure S2 The antioxidant NAC protects against vorino-
stat-induced caspase-3/7 activity. Blasts from an AML
patient were treated with vorinostat and/or NAC for 72 h at
which point caspase-3/7 activity was quantified. Asterisks indicate
a significant difference and a non-significant difference is indicated
as ‘‘n.s’’. (*** ,0.001).
(TIF)
Figure S3 Normal PBMCs are less sensitive to vorino-
stat-induced DNA damage and apoptosis. PBMCs were
collected from healthy volunteers and treated with vorinostat.
A Alkaline COMET assay to measure DNA double strand breaks,
single-strand breaks and alkalile-labile sites. At least 100 nuclei
were randomly selected and quantified for DNA damage,
represented as an increase in Tail Moment (a.u). B Cells were
stained with PI and analyzed by flow cytometry. Apoptosis was
quantified as the percentage of cells with DNA content below that
of the Go-G1 peak (Sub-Go). C Cells were treated with vorinostat
for 72 h and assayed for viability using a luciferase based assay.
D Caspase-3/7 activity (normalized to cell number) was assessed
after 72 h as a marker of apoptosis. Asterisks indicate a significant
difference and a non-significant difference is indicated as ‘‘n.s’’.
(*** ,0.001).
(TIF)
Figure S4 Vorinostat has no effect on DNA repair
protein expression. Protein levels for the DNA repair proteins
Ku70, RAD51 and NBS1 were assayed by western blot. b-Actin
was used as a loading control.
(TIF)
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